E-Cigarettes: No Definitive Evidence on Their Potential Cardiovascular Effect, but Some Suggest Caution

E-cigarettes may bring about cardiac risk according to a new literature review soon to be published in J Am Coll Cardiol. The evidence on potential harm is not definitive, but some experts suggest caution in their use until there is more solid evidence.

E-cigarettes have been advertised as a healthy alternative to traditional cigarettes and an aid for tobacco cessation, but recent evidence suggests that they might cause adverse cardiovascular events.

 

Such events involve endothelial function, vascular stiffness, vasoconstriction, heart rate, blood pressure, inflammation, oxidative stress, and platelet function (all of which have already been observed with e-cigarettes). While e-cigarettes are widely believed to be safe (in terms of both cardiovascular risk and cancer), the truth is that they have not been studied enough. In fact, we could say that there is not enough solid evidence confirming that e-cigarettes even help people to quit smoking conventional cigarettes.


Read also: Several Features Define a Hostile Neck in AAA patients, but Only One Makes the Difference.


These devices can only be considered another tool to help people quit smoking.

 

If they do help smokers to quit conventional cigarettes, their potential for public health benefit is huge. However, this potential benefit must be balanced against their long-term health risks, which are still unknown.

 

Researchers reviewed 14 studies (all of them carried out in developed countries) that suggest possible cardiovascular harm and note that e-cigarettes are available in most countries around the world without any regulation.


Read also: Early Strut Coverage and Its Implications for Dual Antiplatelet Therapy.


We have a responsibility to inform our patients that e-cigarettes contain chemicals whose long-term effects are currently unknown. For smokers, this may be the lesser evil, but we should emphasize the fact that we still lack enough evidence.

 

Original title: 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment.

Reference: Barua RS et al. J Am Coll Cardiol. 2018; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...